This webinar is presented in Chinese.

Alamut™ Visual Plus empowers clinical genomics teams with the tools needed to interpret genetic variants with speed and confidence. This webinar, hosted for the Chinese user community by Yi Lian, Product Director at SOPHiA GENETICS, demonstrates how Alamut™ Visual Plus v2.0 accelerates variant workflows from enhanced navigation and splicing prediction to visualization of bioinformatics files and customizable reporting.

The second webinar in the Precision Oncology Showcase series, sponsored by SOPHiA GENETICS, will highlight the successful decentralization of MSK-ACCESS® on the SOPHiA DDM™ Platform. We will explore findings from our internal verification study, insights from early adopter sites, and real-world data that demonstrate how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) has overcome decentralization challenges—delivering high analytical concordance with single-site testing.

We are also excited to welcome Leah Thompson, MB (ASCP)CM, Lab Technician at Tennessee Oncology, who will share her experience verifying and implementing MSK-ACCESS® powered by SOPHiA DDM™. She will discuss analytical performance, workflow simplicity, and the ease of integrating the solution into a laboratory setting.

Key Discussion Points:

• Decentralizing MSK-ACCESS® – Challenges and solutions for ensuring analytical accuracy, managing site variability, and optimizing workflows.
• Performance & Validation – How the SOPHiA DDM™ Platform maintains high concordance through advanced analytics, noise reduction, and standardized wet-lab processes.
• Real-World Adoption – Leah Thompson, MB (ASCP)CM shares insights on assay verification, workflow efficiency, and the ease of use in routine lab operations.

Learning Objectives:

• Understand the Challenges of Decentralization – Learn about the complexities involved in decentralizing MSK-ACCESS® and how the SOPHiA DDM™ Platform addresses key hurdles such as analytical accuracy, wet-lab standardization, and noise reduction.
• Evaluate Performance and Real-World Verification – Gain insights into the internal verification study results and real-world data from seven early adopter sites, demonstrating high analytical concordance between the decentralized and single-site versions of MSK-ACCESS®
• Explore Ease of Adoption and Workflow Efficiency – Understand how MSK-ACCESS® powered with SOPHiA DDM™ offers a streamlined workflow, reliable data quality, and a straightforward implementation process for laboratories.

June 10, 2026 | 1:00PM SGT

Liquid biopsy (LBx) has emerged as a non-invasive genomic profiling approach to guide decision-making and to monitor resistance in cancer, especially when access to tumor tissue is limited. However, one of the key challenges of LBx is distinguishing somatic variants from clonal hematopoiesis (CH)-derived variants, which can occur in biologically relevant genes and confound variant interpretation. In this webinar, Dr. Keller and Dr. Fares (IUCT Oncopole, France) will explore real-world cases where insights from MSK-ACCESS® powered with SOPHiA DDM™ helped inform decisions. The decentralized liquid biopsy solution integrates matched white blood cell (WBC) DNA sequencing to filter out CH and germline variants, increasing confidence in the somatic origin of detected alterations.

By attending this session, you will gain:

• Practical insights into the clinical utility of liquid biopsy
• An understanding of how CH confounds variant interpretation
• Real-world examples of how matched tumor-normal analysis helps inform decision-making

May 6, 2026 | 1:00PM SGT

MSK-IMPACT is a targeted tissue-based sequencing test for comprehensive genomic profiling. MSK-ACCESS is a liquid biopsy test that enables non-invasive profiling and longitudinal disease monitoring. Together, they provide robust insights that help guide treatment decisions for improved outcomes in patients with advanced cancer. Unlike most tests, MSK leverages matched tumor-normal sequencing to remove germline and clonal hematopoietic variants, revealing genomic alterations of true somatic origin.

In this webinar, A. Rose Brannon, director of clinical bioinformatics at MSK, and Anita S. Bowman, associate director of clinical bioinformatics at MSK, will:

• Highlight the benefits of matched tumor-normal sequencing to reduce biological false positives.
• Discuss the clinical utility of combining tissue- and cell-free DNA-based sequencing approaches, with insights from real clinical cases.
• Explore opportunities for clinical, translational, and basic research.

May 20, 2026 | 1:00PM SGT

Comprehensive genomic profiling (CGP) using a matched tumor-normal approach can help improve somatic detection rate and streamline interpretation.

MSK-IMPACT® powered with SOPHiA DDM™ is a CGP solution that leverages matched tumor-normal sequencing to filter germline variants and may also identify clonal hematopoietic variants, revealing mutations of true somatic origin. The end-to-end application combines the clinical expertise of Memorial Sloan Kettering Cancer Center (MSK) with the robust analytics of SOPHiA DDM™. 

Join us and MSK to:

• Discover the clinical utility of MSK-IMPACT® at MSK.
• Explore the decentralized workflow, robust technology, and analytical performance of MSK-IMPACT® powered with SOPHiA DDM™.

May 27, 2026 | 1:00PM SGT

• Florian Klemm, MD, PhD – Technical Product Manager, SOPHiA GENETICS​
• Ryan Demers, MSc – Global Diagnostics Director, Lung and Liquid Biopsy Strategy, AstraZeneca​
• Persephone du Parcq, MSc, PGDip, - Deputy Operations Lead, Synnovis

MSK-ACCESS® powered with SOPHiA DDM™ offers an innovative and decentralized solution that combines MSK’s expertise in cancer genomics with the robust analytics of the SOPHiA DDM™ Platform. This application aims to address the global inequalities in comprehensive cancer care.​

Watch to hear about the collaborative efforts of SOPHiA GENETICS and AstraZeneca in expanding global access to and adoption of MSK-ACCESS® powered with SOPHiA DDM™. In this session, you will​

• Learn about the decentralized approach, technology, and the analytical performance of this liquid biopsy application.​
• Explore the journey of creating a global network for liquid biopsy testing, including efforts to reach underserved regions where access is limited.​
• Gain insights from the first hands-on experience with MSK-ACCESS® powered with SOPHiA DDM™ from one of the early-access healthcare institutions.​

June 3, 2026 | 1:00PM SGT

Traditional genomic analysis often requires sequential testing or a “one-size-fits-all” comprehensive genomic profiling (CGP) panel, leading to time-consuming workflows and increased costs. MSK-IMPACT® Flex powered with SOPHiA DDM™ is a modular, end-to-end CGP solution built on the expertly designed content of MSK-IMPACT®. The flexible design enables agile analysis and high-resolution profiling of complex biomarkers (including TMB, MSI, HRD, and gene- and exon-level CNVs) from DNA capture, RNA capture, and low-pass whole genome sequencing. 

In this session, you will:  

• Learn how a modular approach simplifies workflows by allowing you to tailor biomarker coverage to each case 
• Explore compelling cases where combined data inputs enhanced the analysis of complex biomarkers 
• Hear real-world insights from OncoHelix on integrating SOPHiA DDM™ into the CGP ecosystem, including the benefits of complementing tissue analysis with tumor-normal liquid biopsy  

Speakers:

Dr. Rehan Mujeeb Faridi, PhD, HCLD/CC (ABB), Director of Molecular Diagnostics, OncoHelix
Lina Li, Director, Product Management, Application, SOPHiA GENETICS
Izabela Matyszczak, Technical Product Management Expert, SOPHiA GENETICS

June 17, 2026 | 1:00 PM SGT

Liquid biopsy has emerged as a revolutionary technology in the precision medicine field, by offering a non-invasive alternative to traditional tumor biopsies. While its potential for tumor detection and monitoring continues to grow, global adoption remains limited due to technical, workflow, and access-related barriers.​ In a leading partnership with AstraZeneca, SOPHiA GENETICS is expanding access to liquid biopsy testing through the deployment of MSK-ACCESS® powered with SOPHiA DDM™, a best-in-class and decentralized NGS-based assay. ​

Join this insightful workshop to explore how a decentralized approach enables broader patient access to testing and accelerates pharmaceutical development, setting new standards in precision oncology.

In this session you will:​

• Discover how the SOPHiA GENETICS decentralised approach and advanced analytics enables scalable, robust, and reproducible liquid biopsy testing, through its decentralized approach, supported by large-scale evidence generation studies across local deployments.​
• Gain insights into the clinical impact and utility of adopting MSK-ACCESS® powered with SOPHiA DDM™, and how it improves access and outcomes for cancer patients.​
• Explore how decentralized testing strategies support late-stage pharmaceutical development and drive commercial success in precision medicine.​

BOSTON, United States and ROLLE, Switzerland, March 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. 

Fourth Quarter 2025 Financial Results 

• Revenue was $21.7 million, up 22% year-over-year 

• Gross margin was 67.7% on a reported basis and 73.9% on an adjusted basis, compared to 68.2% reported and 74.2% adjusted in the prior year period 

• IFRS net loss was $19.2 million, an increase of 27% year-over-year; Adjusted EBITDA loss was $9.9 million, an increase of 9% year-over-year 

Full Year 2025 Financial Results 

• Revenue was $77.3 million, up 19% year-over-year 

• Gross margin was 67.4% on a reported basis and 74.2% on an adjusted basis, compared to 67.4% reported and 72.8% adjusted in the prior year period 

• IFRS net loss was $79.0 million, an increase of 26% year-over-year; Adjusted EBITDA loss was $41.5 million, an increase of 3% year-over-year 

“We finished 2025 strong, with Q4 revenue growing 22% and full-year revenue increasing 19% year-over-year, as our growth momentum continues to accelerate,” said Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS. “We also continued to demonstrate the scalability of our AI-native precision medicine platform, SOPHiA DDM^TM, as adjusted gross margin expanded 140 basis points year-over-year to 74.2% in 2025, even as total terabytes processed by the Platform increased 40% in the same period.” 

Camblong added, “Exceptional new business momentum, including the recent signing of two major integrated health systems in the U.S., which are expected to add 60,000 analyses annually, as well as a record 124 new customers signed in 2025, positions us well for 2026 and beyond. Looking ahead, we expect our primary growth drivers for 2026 to be continued execution in the U.S. market, expansion of our Liquid Biopsy application MSK-ACCESS^® powered with SOPHiA DDM^TM, and renewed momentum in our BioPharma business. We also expect operating leverage to become more pronounced in 2026 as the team and the Platform are now well-positioned to scale with future growth.” 

Business Highlights 

Expanding usage of SOPHiA DDM^TM with existing customers 

• Performed a record 391,000+ analyses in FY 2025, including over 105,000 analyses in Q4 2025 

• Reached 528 core genomics customers as of December 31, 2025, up from 472 customers at the end of 2024 

• Expanded our footprint with existing customers as Net Dollar Retention increased to 115% in 2025, up from 104% in 2024 as customer churn continued to fall 

• Delivered 45% year-over-year analysis growth in North America in Q4 2025 and 32% in Asia Pacific  

Landing new SOPHiA DDM^TM customers to fuel future growth 

• Signed a record 124 new core genomic customers in FY 2025 which will ramp up usage over the next twelve months, up from 92 new customers signed in FY 2024 

• Continued to demonstrate our ability to win larger accounts as the average contract value of new signings was up approximately 120% year-over-year in 2025 

• Signed 30 new customers in Q4 2025, including NYU Langone Health in the United States, AZ Delta system in Belgium, the Human Genome & Stem Cell Research Center in Brazil, and Tyrolpath, one of Austria’s largest pathology labs 

Continued strong business growth in the U.S. market 

• Achieved 50% year-over-year U.S. analysis volume growth in Q4 and 27% growth for FY 2025 

• Signed two of the largest integrated healthcare systems in the U.S. which have committed to using SOPHiA DDM^TM to analyze approximately 60,000 patients annually across the West Coast and Midwest; The accounts are expected to ramp up in the second half of 2026 

• Announced a strategic collaboration with leading U.S. cancer center MD Anderson in Texas to co-develop advanced multimodal oncology testing solutions and accelerate data-driven medicine research 

• Expanded our footprint with existing customers such as Vanderbilt University School of Medicine in Nashville, Memorial Healthcare System in South Florida, and the Icahn School of Medicine at Mount Sinai in New York City, each of which are adopting additional applications 

Accelerating growth with new applications  

• Performed over 7,500 Liquid Biopsy analyses in FY 2025 as customers implement the application and begin to ramp usage 

• Signed over 70 customers to the Liquid Biopsy application MSK-ACCESS^® powered with SOPHiA DDM^TM since its launch, including recent new signings such as the National Institute of Genomic Medicine in Mexico City, the Royal Infirmary of Edinburgh in Scotland, and Vitalité Health Network in Canada 

• Signed a total of 21 customers to the new Solid Tumor applications MSK-IMPACT^® and MSK-IMPACT^® Flex powered with SOPHiA DDM^TM  

Leveraging SOPHiA DDM^TM to deliver value to BioPharma partners 

• Recently signed four contracts with distinct BioPharma partners, reinforcing SOPHiA GENETICS as a trusted leader in AI-driven insights and providing support for 2026 growth 

• Recently agreed to a global commercial agreement with a new top 5 global pharmaceutical company specializing in oncology 

• Continued building on our partnership with Myriad Genetics in the U.S. and A.D.A.M. Innovations in Japan to develop MSK-ACCESS^® powered with SOPHiA DDM^TM into a regulated, global companion diagnostic (CDx) assay, as interest builds amongst BioPharma for this unique, differentiated offering 

Growing sustainably by maintaining an obsession with operational excellence 

• Achieved a 74.2% adjusted gross margin in FY 2025, up 140 basis points year-over-year by continuing to optimize compute costs and leverage the scale of the cloud-native SOPHiA DDM^TM platform 

• Raised $15.5 million in net proceeds from the company’s At-The-Market (ATM) sales program, including $1.1 million raised in Q4 2025 and $14.4 million raised in Q1 2026, executed at a weighted-average price of $5.12 per share; We also expanded our credit facility in January, increasing total available liquidity by $25 million  

• The Company reaffirms commitment to profitable growth and expects to approach adjusted EBITDA breakeven by the end of 2026 and crossing over to positive adjusted EBITDA in the second half of 2027 

2026 Financial Outlook 

Based on information as of today, SOPHiA GENETICS is reaffirming the following guidance:  

• Full-year revenue between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to FY 2025 

• Adjusted EBITDA loss between $29 million and $32 million, compared to $41.5 million in FY 2025  

Earnings Call and Webcast Information 

SOPHiA GENETICS will host a conference call and live webcast to discuss the fourth quarter and full year 2026 results on Tuesday, March 3, 2026, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time. The call will be webcast live on the SOPHiA GENETICS Investor Relations website, ir.sophiagenetics.com. Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.  

Non-IFRS Financial Measures 

Other than with respect to revenue, the Company only provides guidance on a non-IFRS basis. The Company does not provide a reconciliation of forward-looking adjusted gross margin (non-IFRS measure) to gross margin (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses that are necessary for such reconciliation. In addition, the Company does not provide a reconciliation of forward-looking adjusted operating loss (non-IFRS measure) to operating loss (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses and intangible assets, share-based compensation expenses, the non-cash portion of pensions paid in excess of actual contributions, certain transaction costs and litigation expenses that are necessary for such reconciliation. 

To provide investors with additional information regarding the company’s financial results, SOPHiA GENETICS has disclosed here and elsewhere in this earnings release the following non-IFRS measures: 

• Adjusted gross profit, which the company calculates as revenue minus cost of revenue adjusted to exclude amortization of capitalized research and development expenses;  

• Adjusted gross profit margin, which the company calculates as adjusted gross profit as a percentage of revenue;  

• Adjusted operating loss, which the company calculates as operating loss adjusted to exclude amortization of capitalized research and development expenses, amortization of intangible assets, share-based compensation expense, the non-cash portion of pensions expense paid in excess of actual contributions to match the actuarial expense, certain transaction costs and litigation expenses.  

• Adjusted EBITDA, which the company calculates as loss for the period before depreciation, amortization, interest income, interest expense, fair value adjustments on warrant obligations, foreign exchange (losses) gains, net, income tax (expense) benefit, share-based compensation expense, non-cash pension expenses, certain transaction costs and litigation expenses. 

These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans. The exclusion of certain expenses facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain variable charges. Accordingly, the company believes that these non-IFRS measures provide useful information to investors and others in understanding and evaluating its operating results in the same manner as its management and board of directors.  

These non-IFRS measures have limitations as financial measures, and you should not consider them in isolation or as a substitute for analysis of SOPHiA GENETICS’ results as reported under IFRS. Some of these limitations are:  

• These non-IFRS measures exclude the impact of depreciation. Although depreciation is a non-cash charge, the assets being depreciated may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures; 

• These non-IFRS measures exclude the impact of interest expense. Interest expense will continue to be for the foreseeable future a recurring expense based on the company’s financial liabilities; 

• These non-IFRS measures exclude the impact of interest income. Interest income will continue to be for the foreseeable future recurring income based on the company’s financial assets; 

• These non-IFRS measures exclude the impact of income taxes. Income taxes will continue to be for the foreseeable future a recurring expense incurred in the various jurisdictions in which the company operates; 

• These non-IFRS measures exclude the impact of foreign exchange gains (losses),net. Foreign exchange gains and losses will continue to be for the foreseeable future a recurring expense incurred as the company participates in transactions outside of the company’s functional currency; 

• These non-IFRS measures exclude the impact of fair value adjustments of warrant obligations. Fair value adjustments on warrant obligations will continue to be for the foreseeable future a recurring expense incurred as the company has outstanding warrant obligations; 

• These non-IFRS measures exclude the impact of amortization of capitalized research and development expenses and intangible assets. Amortization of these assets will continue to be for the foreseeable future a recurring expense incurred as the Company continues to invest in developing revenue-generating products through research and development. Although amortization is a non-cash charge, the assets being amortized may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures;  

• These non-IFRS measures exclude the impact of share-based compensation expenses. Share-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in the company’s business and an important part of its compensation strategy;  

• These non-IFRS measures exclude the impact of the non-cash portion of pensions paid in excess of actual contributions to match actuarial expenses. Pension expenses have been, and will continue to be for the foreseeable future, a recurring expense in the business;  

• These non-IFRS measures exclude the impact of certain capital markets transaction costs.  These costs may occur from time to time in the future as needed to complete the transactions; 

• These non-IFRS measures exclude the impact of litigation expenses related to the company's defense of lawsuits filed by Guardant Health.  These expenses are expected to continue for the duration of the litigation and may increase in future periods;and 

• Other companies, including companies in the company’s industry, may calculate these non-IFRS measures differently, which reduces their usefulness as comparative measures.   

Because of these limitations, you should consider these non-IFRS measures alongside other financial performance measures, including various cash flow metrics, net income and other IFRS results.  

The tables below provide the reconciliation of the most comparable IFRS measures to the non-IFRS measures for the periods presented.  

Presentation of Constant Currency Revenue 

SOPHiA GENETICS operates internationally, and its revenues are generated primarily in the U.S. dollar, the euro and Swiss franc and, to a lesser extent, British pound, Australian dollar, Brazilian real, Turkish lira and Canadian dollar depending on the company’s customers’ geographic locations. Changes in revenue include the impact of changes in foreign currency exchange rates. We present the non-IFRS financial measure “constant currency revenue” (or similar terms such as constant currency revenue growth) to show changes in revenue without giving effect to period-to-period currency fluctuations. Under IFRS, revenues received in local (non-U.S. dollar) currencies are translated into U.S. dollars at the average monthly exchange rate for the month in which the transaction occurred. When the company uses the term “constant currency”, it means that it has translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. The company then calculates the difference between the IFRS revenue and the constant currency revenue to yield the “constant currency impact” for the current period.  

The company’s management and board of directors use constant currency revenue growth to evaluate growth and generate future operating plans. The exclusion of the impact of exchange rate fluctuations provides comparability across reporting periods and reflects the effects of customer acquisition efforts and land-and-expand strategy. Accordingly, it believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating revenue growth in the same manner as the management and board of directors. However, this non-IFRS measure has limitations, particularly as the exchange rate effects that are eliminated could constitute a significant element of its revenue and could significantly impact performance and prospects. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue and revenue growth presented in accordance with IFRS and other IFRS results. 

The table below provides the reconciliation of the most comparable IFRS growth measures to the non-IFRS growth measures for the current period. 

About SOPHiA GENETICS 

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

Forward-Looking Statements 

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

Investor and Media Contact:  

Kellen Sanger 

[email protected] 

[email protected] 

Streamline variant analysis in Japanese - This webinar is presented in Japanese.

Alamut™ Visual Plus empowers clinical genomics teams with the tools needed to interpret genetic variants with speed and confidence. This webinar, hosted for the Japanese user community by Takeshi Sumida, Implementation Scientist at SOPHiA GENETICS, demonstrates how Alamut™ Visual Plus v2.0 accelerates variant workflows from enhanced navigation and splicing prediction to visualization of bioinformatics files and customizable reporting.